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Background: Supporting self-management behaviours is recommended guidance for people with asthma.
Preliminary work suggests that a brief, intensive, patient-centred intervention may be successful in supporting
people with asthma to participate in life roles and activities they value. We seek to assess the feasibility of
undertaking a cluster-randomised controlled trial (cRCT) of a brief, goal-setting intervention delivered in the context
of an asthma review consultation.
Methods/design: A two armed, single-blinded, multi-centre, cluster-randomised controlled feasibility trial will be
conducted in UK primary care. Randomisation will take place at the practice level. We aim to recruit a total of 80
primary care patients with active asthma from at least eight practices across two health boards in Scotland
(10 patients per practice resulting in ~40 in each arm). Patients in the intervention arm will be asked to complete a
novel goal-setting tool immediately prior to an asthma review consultation. This will be used to underpin a
focussed discussion about their goals during the asthma review. A tailored management plan will then be
negotiated to facilitate achieving their prioritised goals. Patients in the control arm will receive a usual care
guideline-based review of asthma. Data on quality of life, asthma control and patient confidence will be collected
from both arms at baseline and 3 and 6 months post-intervention. Data on health services resource use will be
collected from all patient records 6 months pre- and post-intervention. Semi-structured interviews will be carried
out with healthcare staff and a purposive sample of patients to elicit their views and experiences of the trial. The
outcomes of interest in this feasibility trial are the ability to recruit patients and healthcare staff, the optimal
method of delivering the intervention within routine clinical practice, and acceptability and perceived utility of the
intervention among patients and staff.
Trial registration: ISRCTN18912042
Keywords: Asthma, Goals, Behaviour change, Intervention, RCT, Primary careBackground
Asthma affects more than 300 million people through-
out the world with little evidence of a declining trend in
prevalence [1,2]. In the UK, 5.2 million people are cur-
rently being treated for asthma and an estimated 1 in 7
of the population will be diagnosed with asthma at some
stage in their lives [3]. Although the number of new* Correspondence: gaylor.hoskins@stir.ac.uk
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reproduction in any medium, provided the orcases of childhood asthma appears to be declining, the
prevalence rate for adults continues to rise [4]. Asthma has
a significant effect not only on an individual patient’s
health-related quality of life (HRQoL) [5], but also on soci-
ety and the economy through work absence and premature
retirement [6,7]. Its impact on national health systems is
considerable [4,8,9]. In the UK treatments for asthma and
other allergic disorders account for more than 10% of all
primary care prescribing costs [8]. Asthma management
guidelines recommend that patients with asthma should
be offered self-management support that focusses onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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action plans [10]. The guidance is informed by growing
evidence that personalised asthma management plans—
incorporating a living with asthma plan, asthma medica-
tion plan and asthma action plan [11]—negotiated in the
light of patient goals have the potential to improve a
range of clinical outcomes and quality of life, thereby
resulting in reduced drug bills, hospitalisations and
costs to healthcare systems [10,12-14].
The emphasis on enabling self-management of asthma
has led to a proliferation of asthma action plans being
developed and recommended for routine use within
primary as well as secondary asthma care [10]. Several
studies have subsequently reported that asthma action
plans tend to be under-promoted by health professionals
and under-used by patients and carers, suggesting a
gap between recommended and actual behaviour [15-19].
Further evidence suggested that important factors contrib-
uting to this gap are divergent perceptions of patients and
professionals about asthma and its management and a
mismatch between what patients want/need from these
plans and what is provided by professionals [16,19]. The
asthma action plans that are currently available are limited
in scope, focussing predominantly on symptom manage-
ment strategies (actions) to follow in the presence of de-
teriorating symptoms [14,20]. These medically focussed
plans fail to incorporate patients’/carers’ views of asthma,
its management within the context of their own lives and
their personal asthma management strategies. As a result,
many people with asthma fail to use them to help maxi-
mise their health potential, preferring to self-limit partici-
pation in activity to manage their symptoms [15,16]. To
optimise the impact and use of asthma action plans, it has
been suggested that they need to extend beyond the med-
ical management of asthma to address patient goals in the
wider context of their life and family and incorporate
broader self-management strategies [19]. This is also con-
sistent with current UK health policy, which reflects a
paradigm shift away from the traditional, medical model
of healthcare towards a patient-centred model of care that
promotes collaborative partnership between patients and
professionals in sharing information and agendas, setting
goals and making decisions/plans for treatment and man-
agement [21,22].
The identification of goals is central to both the effect-
iveness and personalisation of self-management plans
[23-25], in particular the likelihood that the plan will lead
to changes in patients’ day-to-day self-management be-
haviours [24]. Goal-setting—a process in which people set
themselves targets and work towards achieving these—is
increasingly recognised as a potentially effective technique
for assisting patients with chronic conditions to improve
health-related behaviours and self-management [23-25].
The theory underlying health-related goal setting suggeststhat goals are more likely to be achieved when they are
specific, important to patients, collaboratively set and
there is a belief that these can be achieved. However, goal
setting reflects only one of the processes involved in the
self-management process [26]. Self-management, broadly
defined as adoption and maintenance of health-improving
behaviours, is conceptualised as comprising two different
processes: motivational and self-regulatory [26,27]. The
motivational process involves forming an intention to en-
gage in a behaviour in order to achieve an outcome (goal)
that is valued or a threat that is to be avoided, a belief that
the behaviour will lead to desirable and valued outcomes,
and a belief that s/he can engage in that behaviour [26].
The self-regulatory process involves translation of the
behavioural intention into action, where ‘planning’ plays a
useful role [28]. Planning consists of two further sub-
processes serving different purposes [28]. The first in-
volves specifying the intended action in terms of when,
where and how to act—termed as action planning; the
second involves anticipating obstacles to action and
making specific plans to overcome them—termed coping
planning. There is considerable evidence to suggest that
action and coping planning increases the likelihood
that patient behaviour will actually change (i.e. that in-
tentions are translated into behaviour) [26-28]. This ap-
proach is supported by evidence showing the effectiveness
of personalised asthma action plans when used in the con-
text of regular reviews [29].
The theoretical underpinnings of self-management
suggest that effective self-management support should
involve interventions that target both the motivational
as well as volitional phases of health behaviour change
[26,27]. As providers of self-management support, health
professionals must work with patients to identify goals
(valued outcomes) that are important to patients, that
may be achievable and with which they can engage as
well as help patients make specific action and coping
plans to achieve those goals. The identification of spe-
cific, personalised goals and associated feasible behav-
iours is a prerequisite for the creation of specific action
and coping plans (i.e. forming an intention that spells
out the when, where and how of goal striving in advance
and planning coping strategies to deal with obstacles).
Despite the central importance of these goals there is
growing evidence to indicate that their identification in
practice is far from easy [19,30]. There is a need there-
fore, to develop new, effective and practical approaches
for eliciting goals and associated self-management be-
haviours by forming partnerships with patients that will
support the self-management agenda [18]. The develop-
ment of a simple goal-setting tool may boost this
process by encouraging patients to focus their thinking
about asthma and its effect on their life. This is an im-
portant step in prioritising management strategies with
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ceptability of using a goal-setting tool within a goal-
setting intervention.
Aims of the study
The primary aim is to pilot the design and process of a
trial to test the effectiveness of a goal-setting interven-
tion in the management of asthma in a primary care set-
ting. We will assess our ability and refine approaches to
recruiting practices, practice staff and patients to a de-
finitive phase III randomised controlled trial (RCT), and
establish the best way of delivering the intervention. Fur-
thermore, we will conduct a value-of-information (VOI)
analysis to inform the optimal sample size for any future
trial [31].
The secondary aims are to estimate the impact of
the goal-setting intervention on patient outcomes as
well as the acceptability and perceived utility by both
patients and health professionals of the goal-setting
tool and the goal-setting process, and to inform the
power of an economic evaluation in the full trial. The
findings from this feasibility study will allow us to
make final relevant modifications to the intervention
prior to RCT development.
Specific objectives
1. To pilot the intervention and its delivery in routine
primary care asthma clinics.
2. To pilot the trial process including recruitment and
performance of outcomes.
Methods/design
Trial design
We are conducting a pragmatic two-armed, multi-centre,
single-blinded, clustered randomised controlled feasi-
bility trial. Primary care practices will be randomly
assigned to either an intervention or a control group.
Patients in the intervention group practices will re-
ceive a goal-setting intervention within a ‘standard’
asthma review consultation. Patients in the control
group practices will receive a ‘standard’ asthma review
alone. Data will be collected from patients and patient
records at baseline (before the intervention) and at
follow-up of 3 and 6 months.
Eligibility of practices for entering the trial
All general practices within two Scottish regional health
boards will be invited to participate. Practices are eligible
if they:
 have an asthma clinic run by a nurse in possession
of an accredited asthma diploma who regularly
reviews and manages patients with asthma. are willing to allow the practice nurse (PN) to
attend a half-day training workshop.
Eligibility of patients for entering the trial
All adults aged 18 years and over with a greater than
1-year history of asthma will be eligible to participate.
Active asthma is defined as a diagnosis of asthma coded
on the practice computer plus a prescription for an
asthma medication in the previous year. Patients will be
excluded if they have chronic obstructive pulmonary dis-
ease (COPD) or any other significant lung disease; are un-
able to give consent because of major medical, social or
communication reasons; or are taking part in any other
clinical trials involving the management of asthma.
Allocation of trial interventions
The general practice is the unit of allocation. Central ran-
domisation by the Tayside Clinical Trials Unit (TCTU) to
intervention or control arms will be carried out separately
for each of the two participating health board areas. This
will be done using minimisation based on achieving
optimum balance for practice list size (two strata <6,000
and >6,001 patients currently registered). The reason for
randomisation by area is to ensure an even distribution of
intervention and control practices as there is potential for
geographical variation in asthma management strategies
between health boards. Thus, within each area two large
and two smaller practices will be matched to receive the
intervention and control. TCTU will tell the research
team of the outcome of the randomisation process and in
turn the practices will be informed of their allocated
group.
Recruitment
General practices and healthcare professionals
The Scottish Primary Care Research Network (SPCRN)
will assist with practice recruitment by writing to the
practices informing them of the study and enclosing an
information sheet, an expression of interest form and a
project practice consent form. Additional informal con-
tact in the form of a project flyer will be made with
practice nurses via the National Health Service (NHS)
Education for Scotland (NES) education facilitators
for the two regions. The Respiratory Managed Clinical
Networks (MCNs) in both areas will be asked to bring the
project to the attention of the practices. Interested prac-
tices will be asked to return the expression of interest
form to the SPCRN administrator. A reminder letter will
be sent by the SPCRN 4 weeks after the initial postal date
with one follow-up phone call 2 weeks later. Active re-
cruitment will cease once at least eight practices (four
in each arm) meeting the eligibility criteria have been
recruited. Once recruited, arrangements will be made with
the practice manager and practice nurse to complete the
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col, patient recruitment and arrangements for pre-study
training. A folder containing the core trial documents will
be given to each participating practice. This will include
an algorithm for selecting patients, patient information
and consent forms, the research team’s contact details and
all trial information.
Patient recruitment
Using the electronic asthma review recall reminder pro-
cedures, practices will be asked to identify all eligible pa-
tients aged 18 years plus due an asthma review within
the proceeding 3-month period. The practice will then
write to potential participants informing them that they
are due an asthma review and that the practice is partici-
pating in the asthma goal project. A template of a cover-
ing letter—stating the study arm to which the practice
has been allocated—has been provided for this purpose
although practices can opt to create/use their own letter.
Patients being aware of the study procedure before
consenting to take part could lead to a difference in the
type of patients participating in the intervention and in
the usual care group. Any differences will be identified
and controlled for in the final analysis. Accompanying
this covering letter will be a project participant informa-
tion sheet, a consent form and a short screening ques-
tionnaire. Interested patients will complete and return
the consent form and the screening questionnaire in a
pre-paid envelope to the Nursing, Midwifery and Allied
Health Professionals research unit (NMHAP-RU) prior to
arranging and attending for their asthma review. Patients
will be asked to express on the screening questionnaire
their preferred day and time to receive a telephone
call. All recruitment materials have been approved by East
of Scotland Research Ethics Committee (REC 2).
Eligible participating patients will be assigned a unique
study identifier and their personal contact details and
the original signed consent form scanned and elec-
tronically stored in a password-protected folder. One
copy of the consent form will be sent to the practice to be
inserted into the trial folder along with a letter informing
the GP/nurse that the patient had consented to participate
in the trial and one copy will be returned to the patient.
The original paper copies will be destroyed in accordance
with data protection guidelines. A thank-you letter will be
sent to all patients who have indicated interest but are not
considered eligible to participate informing them that
their contact details and consent form will be destroyed
safely and in accordance with data protection guidelines.
The goal-setting intervention
The intervention consists of two components—one operat-
ing at patient level and the other at healthcare professional
(HCP) level. At the patient level, the intervention consistsof completion of a goal-setting tool (Additional file 1)
designed to help them clarify goals in the context of their
life and family as well as goals related to the management
of their asthma; a ‘standard’ review of asthma during which
a discussion will take place focussed on the patient’s goals
and priorities; construction of a negotiated, tailored action
plan (Additional file 2). At the level of HCP, it consists of
training in developing shared goals and action plans with
patients to facilitate achievement of the prioritised goals.
The two components are described in detail below. The
intervention draws on the findings from earlier work
[19,30,32,33] as well as established theoretical concepts
and empirical evidence relevant to each specific step in the
intervention process [23-26,28]. This integration of theory
with findings from the primary empirical study strengthens
the basis of the intervention and is supported by rec-
ommendations in the Medical Research Council (MRC)
Framework for Complex Interventions [34]. The control
group receives a ‘standard’ review of asthma only.
Goal-setting tool
The goal-setting tool consists of three sections. It begins
by explaining the meaning and importance of goal set-
ting, the purpose of the tool and instructions on com-
pleting the tool. Section one aims to elicit patients’ goals
in day-to-day life by asking them to write down what
they would really like to do or achieve, list them in order
of priority and indicate whether asthma makes it difficult
to achieve them. Section two aims to establish whether
the goals were important for their own sake (an end in
themselves) or important because they help patients
achieve something else (transitionary). This is done by
asking patients to think about how achieving the goals
would benefit them. Finally section three aims to elicit
goals specific to asthma management, their perceived
importance and patients’ confidence in achieving them.
Each section includes a completed example for illustra-
tive purposes.
Healthcare professional training
Practices allocated to the intervention arm will be asked
to name the practice nurse who will be participating in
the study. All nominated nurses will attend a workshop
where they will receive training on trial procedure, the
components of a ‘standard’ asthma review and the use of
goal setting in the management of asthma. Specifically,
the nurses will be trained in using the information from
the goal-setting tool to focus a discussion with patients
around their life goals and priorities, integrating patient
life goals with asthma management goals, negotiating
and prioritising shared goals, and developing specific ac-
tion plans to facilitate the achievement of those goals.
The workshop will be delivered by the project research
fellows and project PI. The programme for this course is
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practices randomised to the control arm will attend the
first session of the workshop relating to project proced-
ure and asthma review only.
Personalised action plans
To facilitate the achievement of prioritised goals, the pa-
tient, in negotiation with the nurse, will create personalised
action and coping plans. For each goal, they are asked to
identify up to three steps towards the goal, specify the de-
tailed plan for each step, anticipate the obstacles to carry-
ing out the plan and come up with plans to overcome the
obstacles. Following the development of action plans, the
patients are asked to decide whether they would like a
follow-up visit with the nurse, when and whether in-
person or via telephone, to discuss their progress with
implementing the action plans. Follow-up based on clinical
need will be at the discretion of the nurse.
Trial procedures
Once a patient has consented to take part in the trial by
returning the expression of interest form and signed
consent, they will be telephoned by a researcher, at
which time their eligibility to participate in the project
will be confirmed and the baseline questionnaires
completed. Patients will then be asked to contact their
practice and arrange an appointment for an asthma re-
view. The research team will liaise with the general
practice to ensure all consenting patients who have
completed baseline questionnaires have made an ap-
pointment. Patients will be seen by the PN in their
usual clinic setting.
Patients in the intervention group practices will be
sent the goal-setting tool prior to the review appoint-
ment with instructions to complete it independently at
their convenience and to take it with them to the review
appointment. Patients not bringing it to the review will
be asked to complete it in the waiting area prior to the
review.
The nurse in both study groups will conduct a review
consultation in line with clinical guidelines [control as-
sessment; peak expiratory flow (PEF); check of inhaler
technique; review of medication, etc.] In addition the
nurse in the intervention group will review the patient’s
own goals as identified using the goal-setting tool. Nurse
and patient will discuss the individual goals and, if neces-
sary, the appropriateness of and the priority given to each
goal. An individualised action plan will be discussed, nego-
tiated and agreed upon, tailored to the number and com-
plexity of the elicited goals. The written record of the
personalised GOAL action plan will be given to the pa-
tient. This plan will be in addition to any symptom-related
asthma action plan provided by the practice. Nurses in
both the intervention as well as control groups will beasked to audio-record the review consultations using a
digital recorder provided by the research team.
Patients receiving the intervention will be contacted
by the researcher, via the telephone, 6 weeks after their
review consultation to elicit their perceived progress in
implementing their plans and perceived efficacy of the
plans in achieving associated goals. Follow-up outcome
questionnaires will be completed at 3 months and again
at 6 months post review for all patients. Patients will
have the option of receiving these by post and complet-
ing it themselves, or to complete them via the telephone
with a researcher. The former will be supported by a
telephone reminder to patients where necessary.
Measures and measurement instruments
 Asthma-related quality of life: Assessed using the
mAQLQ [35]. The mAQLQ measures the functional
problems experienced by people with asthma. This
is a validated and widely used tool in clinical trials
[36,37] designed to ask adults with asthma about the
physical, emotional occupational, and social
problems most troublesome to them on a day-to-
day basis. A clinically relevant improvement is an
increase of ≥0.5 in individual mAQLQ mean scores.
We will also compare mAQLQ scores at 3-months
post-randomisation to establish the most
appropriate time-point for assessment of clinical
endpoints.
 Asthma Control Questionnaire (ACQ) [38]: The
shortened version of the ACQ has six questions (the
top scoring 5 symptoms and daily rescue
bronchodilator use). Patients are asked to recall how
their asthma has been during the previous week and
to respond to the symptom and bronchodilator use
questions on a 7-point scale (0 = no impairment,
6 = maximum impairment). The questions are
equally weighted and the ACQ score is the mean
of the six questions and therefore between 0
(totally controlled) and 6 (severely uncontrolled).
 Healthcare resource use (HSRU): This is a reflection
of asthma control. Data will be collected from patient
records using a form designed for use in previous
studies [39,40]. Data will include the number
and type of asthma-related consultations, number of
exacerbations, emergency asthma medication use,
etc., in the 6 months pre- and post-intervention.
 Perception of patient empowerment using the Patient
Enablement Instrument [41]: This six-question
(4 responses) tool measures a patient’s confidence,
understanding and ability to cope with their health
and illness.
 Quality of life using the EQ-5D-3 L [42]: Applicable
to a wide range of conditions, this simple
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health outcomes by classifying patients into one of
243 health states (5 dimensions, each with 3 levels).
The five dimensions are mobility, self-care, usual
activities, pain/discomfort and anxiety/depression.
The data are translated into ‘utility scores’ using
the UK population tariff (Dolan, 1995) and used
to estimate Quality Adjusted Life Years in
cost-effectiveness analysis.
Outcome measures
The proposed outcome measures for the definitive trial
have been chosen to reflect both clinical and patient-
centred factors. The main primary outcome measure will
be change in quality of life as measured by the mini
Asthma-related Quality of Life Questionnaire (mAQLQ)
[35]. The proposed secondary outcomes will include
measures of asthma control, healthcare resource use, pa-
tient self-efficacy and cost-effectiveness. Asthma control
will be assessed from the scores on the Asthma Control
Questionnaire (ACQ) [38] and data from the Health
Services Resource Use (HSRU) questionnaire. Cost-
effectiveness will be measured as a cost per Quality-
Adjusted Life Year (QALY) of the intervention compared
to the control group. Utilising the HSRU data, the costs of
overall asthma-related healthcare resource use over the 6-
month pre- and post-trial period from an NHS perspec-
tive will be calculated. QALYs over the 6-month trial
period will be derived from EQ-5D-3L responses [43].
The GOAL-setting process will be assessed by re-
cording the number and type of goals identified and
achieved. This information will be gleaned from the
patient-completed goal setting tool and their level of
confidence for achieving their identified goals from
their completed action plan.
For this pilot trial, the key outcome measures of inter-
est are aimed at enabling us to assess the feasibility of
and plans for conducting the definitive trial:
 Practice and patient recruitment rates
 Retention rates
 Likely cost of the intervention
 Acceptability of GOAL tool and action plan process
to adults with asthma
 The variability of the main outcome measure
 The sample size required to effect change in
asthma-related quality of life
 Acceptability, effectiveness and ease of use of the
chosen measuring instruments
Sample size calculation
As this is a feasibility study we have not undertaken a
formal sample size calculation. A sample size of eight prac-
tices will allow for four practices in each health region.The aim will be to recruit approximately 80 patients in
total (40 in each arm).
Fidelity: practice and practice nurse
Commitment to the project process will be facilitated by
the use of clear written information on what the study
involves; support for recruitment by the SPCRN; use of
individual patient case report forms to log each stage of
the project process; guidance to practices on identifying
eligible patients; a clear account of payment for practice
time; and an extensive training workshop for participat-
ing nurses. The project researchers will be in regular
contact with the practices to offer support, answer any
questions and solve any problems.
Withdrawal of patients from the study
There are five points at which consenting patients could
withdraw from the study:
(1)prior to completing baseline questionnaires
(2)prior to attending the asthma review appointment
with the practice nurse
(3)prior to the 6-week telephone follow-up
(4)prior to completing the 3-month follow-up
questionnaires
(5)prior to completing the 6-month follow-up
questionnaires
Data management
The TCTU will be responsible for data management,
data quality assurance, backup, business recovery and
statistical analysis.
Statistical analysis
Data analysis, using the following analysis plan, will be
undertaken blind to the allocation arm. The primary ana-
lysis will be a per protocol analysis based on an intention
to treat [44].
Descriptive statistics
Describing baseline characteristics of patients and practices
For each study arm, we will describe:
Baseline characteristics of patients: age (mean and SD),
gender (number and percentage), quality of life and
asthma control.
Baseline characteristics of practices: practice list size
(median and IQR, or mean and SD if normally distributed),
number of patients on the practice list with an asthma
code and the number of patients with active asthma
(median and IQR, or mean and SD if normally distributed),
age distribution (number and percentage), and deprivation
and rurality [proxy measures based on the Information
Services Division (ISD) Scotland classification] [45].
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The difference in the validated mAQLQ score between
the intervention and control groups at baseline and 3
and 6 months post-intervention will be compared,
adjusting for practice level stratum (region and list size).
A clinically relevant improvement is an increase of ≥0.5
in individual mAQLQ mean scores [35]. Quality of life
using the validated mAQLQ was measured at the base-
line (January to May 2013) prior to the HCP asthma re-
view appointment, and repeated at 3 months and 6
months post-intervention. Comparison of the mAQLQ
scores at 3 months post-intervention as well as at 6
months post-intervention will enable us to establish the
most appropriate time point for assessment of clinical
endpoints. Changes from baseline to six months post
intervention will be assessed in SPSS for Windows using
multiple regression analysis with 6-month mAQLQ as
outcome and baseline mAQLQ as covariate along with
arm of trial (intervention/control) in the model. We will
be adjusting all models for clustering within practices
and matching by size. Transformations of the outcome
variables will be used where necessary if these are not
normally distributed. All analyses will be stratified by the
stratification factors. We will estimate an ICC for all po-
tential outcomes in the full trial. Consequently sample
size estimates will be made for the full trial.
Cost-effectiveness
Cost-effectiveness of the asthma goal-setting tool will be
measured as a cost per QALY [43]. The incremental
cost-effectiveness ratio (ICER) will be estimated by div-
iding the difference in mean total costs between the
intervention and control group by the difference in
QALYs. Bootstrapping will be used to get an estimate of
variability in the ICER. The economic analysis will in-
clude a VOI analysis [31]. The results of this analysis will
indicate whether the data provided by the phase II feasi-
bility trial are sufficient for decision-making and, if it is
not sufficient, the optimal sample size of a future trial
needed to provide additional information. The VOI
analysis will be based on the estimates of the mean,
variance and covariance of differences in costs and
QALYs obtained from this phase II feasibility trial.
Missing data
mAQLQs
The mAQLQ is divided into four domains, with varying
numbers of questions per domain, and the overall
mAQLQ score is calculated from the mean of each do-
main [35]. Where more than one response is missing
in the symptom or activity domains and any response
missing in the emotional function or environmental
domains, this patient will be excluded from the ana-
lysis [46].Reporting and dissemination
Reporting will adhere to revised CONSORT criteria for
cluster RCTs [47].
Qualitative phase
Qualitative research methods will address three key
questions: how the goal-setting tool was received, how
the elicited information was used, and the effect on work
practice and the self-management process.
Qualitative interviews
As each practice achieves their recruitment target, prac-
tice nurses in both arms of the trial will be invited to take
part in a qualitative interview. In addition, a purposive
sample of patients will be asked to participate in an inter-
view. The patient interviews will be carried out after the
3-month follow-up data have been collected. We hypothe-
sise that the nature of goals and the subsequent experi-
ence of engaging in the goal-setting process is likely to be
influenced by a patient’s gender, age, asthma severity,
deprivation, educational status and the practice nurse.
Therefore, we purposively aim to select patients from both
the genders, from varying age groups, with varying levels
of asthma severity and seeing different nurses. We are
planning for approximately 20 interviews—all of the inter-
vention practice nurses and at least 10 patients. We be-
lieve that with this number we are likely to achieve data
saturation on the questions of interest.
Interviews will be semi-structured and guided by a pa-
tient or professional focussed interview schedule. Patient
interviews will focus on four key topics.
 reasons for and experiences of taking part in the
trial
 acceptability and perceived usefulness of the
goal-setting tool
 experience of and perceived value of the goal-setting
process
 perceived change in the communication with HCPs
 perceived impact on asthma management and
quality of life.
HCP interviews will focus on the following topics:
 experiences and acceptability of all elements of the
trial
 experiences of using the information from the
goal-setting tool and facilitating the development
of personal management plans
 perceived change in communication with patients
 perceived impact on clinical practice
Patients recruited to the study will already have consented
to be part of the interview process. A purposive sample of
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wish to go ahead with the interview. If they agree an inter-
view time will be arranged. Prior to this interview a sec-
ond consent form will be completed. Interviews will be
conducted in a confidential, private setting, e.g., the pa-
tient’s home or the health professional’s place of work.
Telephone interviews will be considered if face-to-face in-
terviews prove difficult to arrange. Interviews will be
conducted by the same interviewer and are expected to
last an average of 30–45 min. All interviews will be audio-
recorded, transcribed verbatim and checked for accuracy.
The interview transcripts will be returned to the inter-
viewees for verification.
Data management and analysis
All interview transcripts will be given a project code at
the point of collection. Any identifiable data will be
changed to ensure anonymity for participants. All the
qualitative data will be managed using the data manage-
ment software NVivo 9. Data will be analysed following
the guidelines for thematic framework analysis [48],
which allows systematic classification and organisation
of the data in terms of key themes and emergent pat-
terns. The analytical process will be an iterative one with
new issues identified during interim data analysis in-
cluded in subsequent interviews. An initial coding frame
will be developed using data from the first few tran-
scripts and key concepts from the psychological theories
underlying the intervention. The coding frame will then
be applied systematically to all the transcripts, adding
new themes and categories as they emerge from the
data. Once all the text has been coded, the coding frame
will be refined by revisiting and sorting the text in each
category, searching for association among different
themes and grouping them under more comprehensive,
higher order themes. Various strategies will be employed
throughout the data analysis to ensure trustworthiness
of the data: content checking of the transcripts by the
interviewees, data coding and checking for accuracy by
two researchers, constantly searching for alternative ex-
planations, and discussion of emerging themes and pat-
terns with the wider research and project management
team. The findings from the qualitative research will be
merged with the findings from the quantitative data and
used to design the full RCT.
Recordings of asthma reviews
All consultations, whether in the intervention or control
arm, will be recorded and listened to independently. This
will allow us to check the fidelity of the review process.
Trial steering committee
The Feasibility Trial Steering Committee (FTSC) will moni-
tor and supervise the trial and comment on any proposedamendments to the protocol. The FTSC is chaired by Dr
Gaylor Hoskins. Professor Brian Williams, Professor Aziz
Sheikh, Professor Peter Donnan, Dr Hilary Pinnock, and Dr
Marjon van der Pol are study co-applicants and sit on the
FTSC. Dr Purva Abhyankar and Dr Anne Taylor, the re-
search managers for the study, also sit on this group. Mr
Gordon Brown (Asthma UK Scotland) and Mrs Wendy
Nganasurian represent the patient perspective. Professor
Chris Griffiths is acting as an independent monitor for the
study. The FTSC has agreed to operate within the frame-
work suggested in the MRC Guidelines for good clinical
practice in clinical trials [49].
Ethical considerations
The clinical trial will be conducted according to the
Helsinki Declaration [50], Good Clinical Practice guidelines
[49] and NHS research governance requirements. Patients
who have agreed to allow the study team to access their
clinical records have provided written informed consent.
All patients were made aware that they could withdraw
from the research at any time. The study has been ap-
proved by the East of Scotland Research Ethics Committee
(REC ref. no. 12/ES/0050). All appropriate NHS Research
and Development approvals have been obtained.
Study timeline
 Trial start: 1 October 2012
 Baseline data collection: From January 2013 until all
patients have been recruited
 Interventions in general practice: January 2013
(training); January 2013 onwards (patient recruitment),
February 2013 onwards (patient review appointments
with PNs)
 End of interventions and follow-up in general
practice: November 2013
 Qualitative interviews: July to November 2013
 Start of data analysis: November 2013
 Planned study end date: end December 2013
 Duration: 15 months
Trial status
At the time of submission ten practices are participating
in the trial and patients are currently being recruited.
Additional files
Additional file 1: Goal-setting tool.
Additional file 2: Goal action plan.
Additional file 3: Practice nurse training schedule.
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